{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:09:07Z","timestamp":1788635347990,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jdiacomp.2021.108056","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T21:11:26Z","timestamp":1633641086000},"page":"108056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Xingjian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2021.108056_bb0005","first-page":"3","article-title":"Diabetic nephropathy: an overview","volume":"2067","author":"Sagoo","year":"2020"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062218","article-title":"Glucose and blood pressure-dependent pathways-the progression of diabetic kidney disease","volume":"21","author":"Patel","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11892-019-1133-6","article-title":"The global burden of diabetic kidney disease: time trends and gender gaps","volume":"19","author":"Thomas","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0025","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on diabetic nephropathy: core curriculum 2018","volume":"71","author":"Umanath","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0030","first-page":"738","article-title":"Neprilysin inhibition in chronic kidney disease","volume":"30","author":"Judge","year":"2015"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","article-title":"Effect of neprilysin inhibition on various natriuretic peptide assays","volume":"73","author":"Ibrahim","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MNH.0000000000000659","article-title":"TaleNeprilysin and neprilysin inhibition in chronic kidney disease","volume":"30","author":"Judge","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0045","first-page":"103","article-title":"Sacubitril\/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation","volume":"128","author":"Mochel","year":"2019"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0055","doi-asserted-by":"crossref","first-page":"F1047","DOI":"10.1152\/ajprenal.00164.2014","article-title":"ANP-induced signaling cascade and its implications in renal pathophysiology","volume":"308","author":"Theilig","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.2015070731","article-title":"Natriuretic peptide receptor guanylyl cyclase-a in podocytes is renoprotective but dispensable for physiologic renal function","volume":"28","author":"Staffel","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0065","article-title":"Particulate guanylyl cyclase A\/cGMP signaling pathway in the kidney: physiologic and therapeutic indications","volume":"19","author":"Chen","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/jbcpp-2017-0146","article-title":"Role of atrial natriuretic peptide in controlling diabetic nephropathy in rats","volume":"29","author":"Singh","year":"2018","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0075","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0080","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00125-003-1121-9","article-title":"Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy","volume":"46","author":"Davis","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0085","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/13543784.2017.1317345","article-title":"Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug","volume":"26","author":"Gervasini","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0090","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0022-3565(25)22094-8","article-title":"Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney","volume":"246","author":"Loutzenhiser","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0095","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14364","article-title":"Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db\/db diabetic mice","volume":"8","author":"Alawi","year":"2020","journal-title":"Physiol Rep"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11897-020-00463-1","article-title":"Impact of sacubitril-valsartan on markers of glomerular function","volume":"17","author":"Tersalvi","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Vajir Malek","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0110","first-page":"159","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O'Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0115","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/HYPERTENSIONAHA.119.12676","article-title":"Emerging drug classes and their potential use in hypertension","volume":"74","author":"Azizi","year":"2019","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0120","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0125","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0130","article-title":"Effect and safety of LCZ696 in the treatment of hypertension: a meta-analysis of 9 RCT studies","volume":"98","author":"Li","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0135","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1167\/iovs.16-20289","article-title":"Beneficial effects of combined AT1 Receptor\/Neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye","volume":"57","author":"Prasad","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/cvr\/cvy226","article-title":"Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy","volume":"115","author":"Malek","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0145","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.biopha.2016.10.089","article-title":"The role of natriuretic peptides in diabetes and its complications","volume":"84","author":"Ying Feng","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0150","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1172\/JCI113120","article-title":"Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration","volume":"80","author":"Ortola","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejphar.2018.02.007","article-title":"Neprilysin inhibition and endothelin-1 elevation: focus on the kidney","volume":"824","author":"Roksnoer","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.336","article-title":"Prevention against renal damage in rats with subtotal nephrectomy by sacubitril\/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor","volume":"5","author":"Ushijima","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","article-title":"Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy","volume":"221","author":"Malek","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0170","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0175","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1755-5922.12183","article-title":"Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction","volume":"34","author":"Kobalava","year":"2016","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0185","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1042\/CS20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone","volume":"130","author":"Roksnoer","year":"2016","journal-title":"Clin Sci (London, England: 1979)"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0190","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9196","article-title":"LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-\u03baB mediated inflammation and glomerulosclerosis in rats","volume":"8","author":"Mohany","year":"2020","journal-title":"PeerJ"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0195","first-page":"755","article-title":"Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury","volume":"38","author":"Uijl","year":"2020"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0200","first-page":"5473","article-title":"LCZ696 (Sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD","volume":"9","author":"Jing","year":"2017","journal-title":"Am J Trans Res"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-019-0847-8","article-title":"The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker obese rat","volume":"18","author":"Habibi","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0210","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jphs.2019.09.014","article-title":"The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats","volume":"142","author":"Rahman","year":"2020","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0215","doi-asserted-by":"crossref","first-page":"F1133","DOI":"10.1152\/ajprenal.00614.2020","article-title":"db\/dbSacubitril\/valsartan treatment has differential effects in modulating diabetic kidney disease in mice and KKAy mice compared with valsartan treatment","volume":"320","author":"Myakala","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0220","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1152\/ajprenal.00125.2020","article-title":"Differential effects of low-dose sacubitril and\/or valsartan on renal disease in salt-sensitive hypertension","volume":"319","author":"Polina","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0225","doi-asserted-by":"crossref","first-page":"2615286","DOI":"10.1155\/2017\/2615286","article-title":"Research Progress on mechanism of podocyte depletion in diabetic nephropathy","volume":"2017","author":"Dai","year":"2017","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0230","doi-asserted-by":"crossref","first-page":"F393","DOI":"10.1152\/ajprenal.00186.2015","article-title":"TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases","volume":"309","author":"Ilatovskaya","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2017.12.010","article-title":"LCZ696 (Sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis and vasculopathy in a rat model of chronic kidney disease","author":"Suematsu","year":"2018","journal-title":"J Card Fail"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0240","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/obr.12598","article-title":"Natriuretic peptides in the control of lipid metabolism and insulin sensitivity","volume":"18","author":"Verboven","year":"2017","journal-title":"Obes Rev"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0245","doi-asserted-by":"crossref","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0250","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820970444","article-title":"Potential mechanisms of beneficial effect of sacubitril\/valsartan on glycemic control","volume":"11","author":"Seferovic","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cpt.455","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","volume":"101","author":"Jordan","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0260","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00125-019-4889-y","article-title":"Neprilysin inhibition: a new therapeutic option for type 2 diabetes?","volume":"62","author":"Esser","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0265","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.7150\/ijms.49373","article-title":"Angiotensin II receptor neprilysin inhibitor (LCZ696) compared to valsartan attenuates hepatotoxicity in STZ-induced hyperglycemic rats","volume":"17","author":"Alqahtani","year":"2020","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0275","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0280","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.nefro.2019.01.005","article-title":"Sacubitril\/valsartan in chronic kidney disease, the nephrologist point of view","volume":"39","author":"Quiroga","year":"2019","journal-title":"Nefrologia"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0285","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/hr.2015.1","article-title":"Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in japanese patients with hypertension and renal dysfunction","volume":"38","author":"Ito","year":"2015","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0290","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-020-01022-7","article-title":"Report from the 5th cardiovascular outcome trial (CVOT) summit","volume":"19","author":"Schnell","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0300","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2362.1999.00422.x","article-title":"Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption","volume":"29","author":"Jacobs","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0310","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0315","first-page":"595","article-title":"Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors","volume":"473","author":"Brignone","year":"2021"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"Kang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0325","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCULATIONAHA.118.036523","article-title":"Neprilysin inhibition and effects on kidney function and surrogates of cardiovascular risk in chronic kidney disease","volume":"138","author":"James","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0330","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"ancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0335","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2213-8587(17)30177-8","article-title":"Sacubitril\/valsartan in PARADIGM-HF","volume":"5","author":"Vodovar","year":"2017","journal-title":"ancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0340","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ejhf.1185","article-title":"Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0345","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/atm-20-4038","article-title":"Narrative review in the current role of angiotensin receptor-neprilysin inhibitors","volume":"9","author":"Cruz Rodriguez","year":"2021","journal-title":"Ann Trans Med"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0350","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12272","article-title":"Pharmacogenomics of angiotensin receptor\/neprilysin inhibitor and its long-term side effects","volume":"35","author":"Krittanawong","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173851","article-title":"Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!","volume":"894","author":"Poorgolizadeh","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0360","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0365","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/1932296818785644","article-title":"Reduction of insulin requirement after starting treatment with sacubitril\/valsartan in a patient with diabetes treated with continuous subcutaneous insulin infusion (CSII): a case report","volume":"12","author":"Gamarra","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0370","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cjco.2020.02.002","article-title":"Severe hypoglycemia in a patient with type 1 diabetes mellitus recently started on sacubitril\/valsartan: a case report","volume":"2","author":"Barry","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0375","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1681\/ASN.V5122057","article-title":"Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus","volume":"5","author":"Zietse","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108056_bb0380","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1055\/a-0603-3792","article-title":"Relationship between the brain natriuretic peptide (BNP) level and prognosis of diabetic nephropathy with microalbuminuria: a 7-year follow-up study","volume":"50","author":"Seki","year":"2018","journal-title":"Horm Metab Res"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721002701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721002701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:14:08Z","timestamp":1761005648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872721002701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1056872721002701"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.108056","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.108056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"108056"}}